Serum Levels of PCSK9 Are Increased in Patients With Active Ulcerative Colitis Representing a Potential Biomarker of Disease Activity: A Cross-sectional Study

• Published in: Journal of clinical gastroenterology Vol. 56; no. 9; p. 787
• Main Authors: Marinelli, Carla, Zingone, Fabiana, Lupo, Maria Giovanna, Marin, Raffaella, D'Incà, Renata, Gubbiotti, Alessandro, Massimi, Davide, Casadei, Cesare, Barberio, Brigida, Ferri, Nicola, Savarino, Edoardo
• Format: Journal Article
• Language: English
• Published: United States 01.10.2022
• Subjects: Adult; Aged; Biomarkers; C-Reactive Protein - analysis; Colitis, Ulcerative - diagnosis; Colonoscopy; Cross-Sectional Studies; Feces - chemistry; Female; Humans; Inflammation; Leukocyte L1 Antigen Complex - analysis; Male; Middle Aged; Proprotein Convertase 9 - analysis; Proprotein Convertase 9 - metabolism; Severity of Illness Index
• ISSN: 1539-2031
• DOI: 10.1097/MCG.0000000000001607

Ulcerative colitis (UC) is characterized by chronic inflammation and progressive course, with potential extraintestinal complications including cardiovascular mortality. Serum proprotein convertase subtilisin/kexin type 9 (PCSK9) levels have been recently recognized as biomarkers of low-grade inflammation and cardiovascular disease. The aim of our study was to evaluate PCSK9 levels in patients with UC and different degrees of disease activity. We prospectively recruited consecutive patients with UC attending our center at the University Hospital of Padua. Demographics, clinical characteristics, and biochemical data, including PCSK9, high sensitivity C-reactive protein, and fecal calprotectin, were recorded. Moreover, endoscopic procedures were performed in all subjects. We included 112 patients with UC (mean age=52.62±12.84 y; 52.62% males). Patients with UC and abnormal fecal calprotectin (≥250 µg/g) and/or C-reactive protein (≥3 mg/L) had greater levels of PCSK9 compared with UC patients with normal fecal calprotectin and high sensitivity C-reactive protein ( P =0.03 and 0.005, respectively). Higher endoscopic scores in UC were characterized by greater levels of PCSK9 ( P =0.03). Furthermore, we found a positive correlation between PCSK9 levels and fecal calprotectin ( r =0.18, P =0.04), endoscopic Mayo Score ( r =0.25, P =0.007), and UC-Riley Index ( r =0.22, P =0.01). We also found a positive correlation between PCSK9 levels and both total and low-density lipoprotein cholesterol values ( P <0.05). Serum PCSK9 levels are increased in patients with biochemical and endoscopic evidence of active disease in UC. Further longitudinal studies are necessary to evaluate the role of PCSK9 as a potential biomarker of disease activity and cardiovascular risk in UC.